AMT-253
Phase 1- Indications
- Melanoma
Company intelligence / Profile preview
CTCA was a national for-profit network specializing in comprehensive and integrative oncology care for complex and advanced-stage cancers. It offered surgery, chemotherapy, radiation therapy, immunotherapy and supportive/integrative therapies. The organization participated in clinical studies such as ASCO’s TAPUR trial but was primarily focused on patient care rather than drug development[1][4].
After being acquired by City of Hope in early 2022 for $390 million[1], all locations were rebranded under the City of Hope name in early/mid–2023[7]. The combined entity now operates as a non-profit with an expanded national footprint.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cancer Treatment Centers of America.